Industry & Policy News

[Brain Cancer Canada] The grant will fund an innovative project by Dr. Maria MacDonald of the London Health Sciences Centre and Drs. Julie Bennett and Cynthia Hawkins of the Hospital for Sick Children. They are working to identify the proportion of adults with brain tumors with a genetic profile typically seen in children.

[Plus Therapeutics, Inc.] Plus Therapeutics, Inc. announced an expansion of its collaboration with Piramal Pharma Solutions to produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium obisbemeda, for ongoing and planned clinical trials.

[BioCardia®, Inc.] BioCardia®, Inc. announced that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039.

[Radiopharm Theranostics] Radiopharm Theranostics announced that the US FDA has granted Orphan Drug Designation to Ga68-Trivehexin, RAD 301, radiopharmaceutical technology for imaging of patients with PDAC.

[Editas Medicine, Inc.] Editas Medicine, Inc. announced that the US FDA granted Orphan Drug Designation to EDIT-301, an investigational, gene-editing medicine, for the treatment of sickle cell disease.

[Academic Pediatrics] Bristol Myers Squibb announced that the European Commission has granted approval for Breyanzi, a CD19-directed CAR T cell therapy, for relapsed or refractory large B cell lymphoma after one prior therapy.